Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Etoposide
Drug ID BADD_D00854
Description A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Indications and Usage For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
Marketing Status Prescription; Discontinued
ATC Code L01CB01
DrugBank ID DB00773
KEGG ID D00125
MeSH ID D005047
PubChem ID 36462
TTD Drug ID D0B7EB
NDC Product Code 0143-9376; 53104-7514; 16729-114; 57884-0008; 0378-3266; 53183-8538; 0143-9510; 55361-0006; 68001-265; 0703-5656; 0703-5653; 63323-104; 0703-5657; 0143-9511; 0143-9512
Synonyms Etoposide | Eposide | Demethyl Epipodophyllotoxin Ethylidine Glucoside | Eto-GRY | Eto GRY | Etoposide, (5a alpha,9 alpha)-Isomer | Etoposide, (5S)-Isomer | Etoposide, alpha-D-Glucopyranosyl Isomer | Etoposide, alpha D Glucopyranosyl Isomer | alpha-D-Glucopyranosyl Isomer Etoposide | Etoposido Ferrer Farma | Exitop | Lastet | NSC-141540 | NSC 141540 | NSC141540 | Onkoposid | Riboposid | Toposar | Etoposide Teva | Teva, Etoposide | Vepesid | VP 16-213 | VP 16 213 | VP 16213 | VP-16 | VP 16 | VP16 | Vépéside-Sandoz | Vépéside Sandoz | Celltop | Etopos | Etomedac | Eposin | Etoposide, (5a alpha)-Isomer | Etoposide Pierre Fabre
Chemical Information
Molecular Formula C29H32O13
CAS Registry Number 33419-42-0
SMILES CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC) O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.003197%
Abdominal pain upper07.01.05.003--
Acute leukaemia01.10.02.001; 16.01.02.001--Not Available
Acute lymphocytic leukaemia01.10.01.001; 16.01.01.0010.000208%Not Available
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.001181%Not Available
Acute promyelocytic leukaemia01.10.05.003; 16.01.05.0030.001066%Not Available
Acute respiratory distress syndrome22.01.03.0010.000208%
Agranulocytosis01.02.03.0010.001865%Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Anaemia01.03.02.0010.008259%
Anaphylactic reaction10.01.07.001; 24.06.03.0060.004795%
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Anxiety19.06.02.002--
Aplasia03.02.01.002; 08.03.04.0030.002664%Not Available
Apnoea22.02.01.001--
Arthralgia15.01.02.001--
Ascites02.05.04.002; 07.07.01.001; 09.01.05.003--
Aspartate aminotransferase increased13.03.01.0060.000533%
Asthenia08.01.01.0010.002664%Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.0050.003730%
Blindness cortical06.02.02.004; 17.17.01.017--Not Available
Blood albumin decreased13.09.01.001--Not Available
Blood creatinine increased13.13.01.0040.000799%
Blood pressure decreased13.14.03.0020.001332%Not Available
Blood pressure increased13.14.03.005--Not Available
Blood uric acid increased13.02.04.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene